Danen Cunoosamy
- Expression of CX3CL1 and CX3CR1 in human asthmatic lung in relation to cell survivalBy Danen Cunoosamy, Xiao-Hong Zhou, Maria Rehnberg, Karin Svensson and Kristian SandbergDanen Cunoosamy1AstraZeneca Innovative Medicines, Respiratory, Inflammation and Autoimmunity, Bioscience, Mölndal, SwedenXiao-Hong Zhou2AstraZeneca Innovative Medicines, Respiratory, Inflammation and Autoimmunity, Translational Sciences, Mölndal, SwedenMaria Rehnberg2AstraZeneca Innovative Medicines, Respiratory, Inflammation and Autoimmunity, Translational Sciences, Mölndal, SwedenKarin Svensson1AstraZeneca Innovative Medicines, Respiratory, Inflammation and Autoimmunity, Bioscience, Mölndal, SwedenKristian Sandberg2AstraZeneca Innovative Medicines, Respiratory, Inflammation and Autoimmunity, Translational Sciences, Mölndal, Sweden
- Differential sensitivity of subsets of monocyte-derived macrophages to apoptosis; its impact on lung inflammationBy Nisha Kurian and Danen CunoosamyNisha Kurian1Respiratory, Inflammation & Autoimmunity iMed, AstraZeneca, Mölndal, SwedenDanen Cunoosamy2Respiratory, Inflammation & Autoimmunity iMed, AstraZeneca, Mölndal, Sweden
- Demonstration of anti-inflammatory properties of an inhaled p38 inhibitor AZD7624By Danen Cunoosamy, Katerina Pardali, Naimish Patel and Jansson PaulDanen Cunoosamy1RIA IMED, AstraZeneca R&D, Mölndal, SwedenKaterina Pardali1RIA IMED, AstraZeneca R&D, Mölndal, SwedenNaimish Patel2RIA IMED, AstraZeneca R&D, Boston, United StatesJansson Paul1RIA IMED, AstraZeneca R&D, Mölndal, Sweden
- Pre-clinical to clinical potency of AZD7624 in LPS induced TNFa responseBy Rikard Pehrson, Tove Hegelund, Sofia Lundin, Patel Naimish, Paul Jansson and Danen CunoosamyRikard PehrsonRIA iMED, AstraZeneca, Mölndal, SwedenTove HegelundRIA iMED, AstraZeneca, Mölndal, SwedenSofia LundinRIA iMED, AstraZeneca, Mölndal, SwedenPatel NaimishRIA iMED, AstraZeneca, Mölndal, SwedenPaul JanssonRIA iMED, AstraZeneca, Mölndal, SwedenDanen CunoosamyRIA iMED, AstraZeneca, Mölndal, Sweden
- AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humansBy Naimish Patel, Danen Cunoosamy, Tove Hegelund-Myrback, Rikard Pehrson, Ziad Taib, Paul Jansson, Sofia Lundin, Steven Greenaway, Graham Clarke and Leonard SiewNaimish Patel1Early Clinical Development, AstraZeneca R&D, Waltham, MA United StatesDanen Cunoosamy2iMed Respiratory/Inflammation, AstraZeneca R&D, Mölndal, SwedenTove Hegelund-Myrback3RIA iMed DMPK, AstraZeneca R&D, Mölndal, SwedenRikard Pehrson2iMed Respiratory/Inflammation, AstraZeneca R&D, Mölndal, SwedenZiad Taib4ECD Biostatistics, AstraZeneca R&D, Mölndal, SwedenPaul Jansson3RIA iMed DMPK, AstraZeneca R&D, Mölndal, SwedenSofia Lundin3RIA iMed DMPK, AstraZeneca R&D, Mölndal, SwedenSteven Greenaway5Quintiles Drug Research Unit at Guy's Hospital, London, United KingdomGraham Clarke5Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom6Department of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, United KingdomLeonard Siew5Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.